REGN9533 / Regeneron - LARVOL DELTA

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of REGN9533, a monoclonal antibody targeting Factor XII (FXII), in healthy adults: Results from a Phase 1, randomised, double-blind, placebo-controlled study (ISTH 2026) - P1 | "This study was funded by Regeneron Pharmaceuticals, Inc. DOI*10.1016/j.rpth.2026.103618 Page 2"

Clinical • P1 data • PK/PD data • Cardiovascular • Hematological Disorders • Infectious Disease • Inflammation • Thrombosis

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open